Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: Array BioPharma Inc. (ARRY) Report Updated: Oct 17, 2016 | Print This Page

Get more stock ratings by Louis Navellier

Array BioPharma Inc. (ARRY)

Rating: Hold Volatility: Aggressive
Total Grade: C Industry: Biotechnology

Stock Analysis

Rating: Monthly View

October November December January February March April May June July August September

Rating: Weekly View

This Week: C down downgrade
Last Week: B same upgrade
Two Weeks Ago: D up no change
service keys

Array BioPharma Inc.© quotemedia

Company Profile

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company’s drugs in Phase III clinical trials include Binimetinib and Encorafenib for the treatment of cancer. Its drug candidates in Phase II clinical trials include Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy; ASC08/Danoprevir, a protease inhibitor for Hepatitis C virus; ASLAN001/ARRY-543, a pan-HER inhibitor for gastric or breast cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; Motolimod/VTX-2337, a toll-like receptor for cancer; and LY2606368, a chk-1 inhibitor for cancer. The company’s Phase Ib drug candidate comprises GDC-0575, a chk-1 inhibitor for cancer; and ONT-380/ARRY-380, a HER2 inhibitor for breast cancer, as well as Phase I drug candidate includes GDC-0994, an ERK inhibitor for cancer and LOXO-101, a PanTrk inhibitor for cancer. Array BioPharma Inc. has collaboration agreements with Biogen Idec MA Inc.; Array and Celgene Corporation and Celgene Alpine Investment Co., LLC; Genentech, Inc.; Loxo Oncology, Inc.; Novartis International Pharmaceutical Ltd.; and Oncothyreon Inc, as well as a collaboration with Dana-Farber Cancer Institute. The company was founded in 1998 and is headquartered in Boulder, Colorado.